List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
Using X-ray crystallography, researchers have revealed the structure of the SARS-CoV-2 main protease, designing an inhibitor to bind to this target and prevent viral replication.
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
Researchers have demonstrated that in mice, a newly developed heparan sulfate molecule can provide an effective alternative treatment for overdoses of acetaminophen.
Researchers have shown a gene therapy to correct the genetic mutation that causes Danon disease is successful in pre-clinical trials.
Scientists have imaged the ball-and-chain mechanism using cryogenic electron microscopy and hope their work could be applied in the design of novel therapeutics.
Scientists have created an artificial protein able to recognise and bind cell surface carbohydrates with high affinity and selectivity.
Using nuclear magnetic resonance spectroscopy, a study has shown that IL-2 can stimulate both effector T cells and regulatory T cells by adopting different structural forms.
A new Cas13 RNA screen has been used to establish guide RNAs for the COVID-19 coronavirus and human RNA segments which could be used in vaccines, therapeutics and diagnostics.
AbCellera and Eli Lilly have announced their partnership to develop, manufacture and distribute antibody treatments for the COVID-19 coronavirus.
A star-shaped molecule along with a modified platinum drug have demonstrated success at combatting tumours with few toxic effects in mice.
Pre-clinical studies demonstrate that inhibiting the ’epichaperome’ can restore neural networks to normal levels. Dr Barbara Wallner at Samus Therapeutics explains how targeting the epichaperome could work as a potential treatment for Alzheimer’s and other neurodegenerative diseases.
Researchers have developed a new screening technique by inactivating the molecular structure of the human muscarinic receptor, allowing them to test potential drugs.
A new 3D model of the surface of the coronavirus COVID-19 has been released, to aid researchers in the development of a treatment.
